10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Rating of “Hold” by Analysts

Shares of 10x Genomics, Inc. (NASDAQ:TXG) have been given a consensus rating of “Hold” by the seventeen ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $20.57.

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Wednesday, February 19th. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $25.00 to $12.00 in a report on Thursday, February 13th. UBS Group lowered their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Citigroup cut their price objective on 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 13th.

Institutional Trading of 10x Genomics

A number of hedge funds have recently modified their holdings of TXG. RA Capital Management L.P. acquired a new position in 10x Genomics in the fourth quarter worth about $47,092,000. Assenagon Asset Management S.A. bought a new position in shares of 10x Genomics during the 4th quarter worth approximately $26,308,000. ARK Investment Management LLC boosted its stake in 10x Genomics by 15.4% in the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after buying an additional 1,436,582 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in 10x Genomics in the 3rd quarter valued at $27,778,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in 10x Genomics in the fourth quarter valued at $17,499,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

TXG stock opened at $10.90 on Wednesday. The stock has a market capitalization of $1.33 billion, a PE ratio of -7.17 and a beta of 1.85. The company has a fifty day moving average of $14.31 and a 200-day moving average of $17.08. 10x Genomics has a one year low of $10.80 and a one year high of $48.42.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.